Therapeutic FocusNarrow moat

Lilly concentrates its research in a handful of therapeutic areas — diabetes and metabolism, oncology, immunology, and neuroscience — rather than spreading itself thin across all of medicine, and that focus is a genuine strategic advantage. Deep expertise in a few areas compounds: the scientists, the data, the relationships with specialists, and the understanding of a disease all reinforce one another, so a company steeped for decades in metabolic disease is better placed to make the next breakthrough in it than a generalist dabbling everywhere. Focus turns accumulated knowledge into an edge.

The incretin success is itself a product of this focus. Lilly's long, deep investment in diabetes and metabolism — decades of insulin, of studying the relevant biology, of relationships with endocrinologists — is what positioned it to develop and win the tirzepatide franchise. Expertise in a therapeutic area is cumulative and self-reinforcing: each advance deepens the understanding that enables the next, and the concentrated knowledge base becomes a platform from which a company can out-innovate less-focused rivals in its chosen fields.

The trade-off is that focus means concentration, and concentration is a double-edged sword. Betting heavily on a few therapeutic areas magnifies the impact of success — as the incretin boom shows — but also the impact of a setback in one of them, and it means missing opportunities in areas Lilly has chosen not to pursue. So therapeutic focus is a real advantage that has demonstrably paid off, compounding expertise into breakthroughs in Lilly's chosen fields — but a strategy that ties the company's fortunes more tightly to a few areas of medicine, for better and for worse — cardiometabolic medicines were 79.9% of revenue in the second quarter of 2026.¹²